149 related articles for article (PubMed ID: 14632776)
1. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Keating MJ; Kantarjian HM; Armitage JO; Albitar M
Br J Haematol; 2003 Dec; 123(5):850-7. PubMed ID: 14632776
[TBL] [Abstract][Full Text] [Related]
2. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G; Albitar M; O'Brien S; Wang X; Manshouri T; Faderl S; Ferrajoli A; Burger J; Garcia-Manero G; Kantarjian HM; Lerner S; Keating MJ; Wierda WG
Br J Haematol; 2010 Feb; 148(3):386-93. PubMed ID: 19895616
[TBL] [Abstract][Full Text] [Related]
3. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Manshouri T; Do KA; Wang X; Giles FJ; O'Brien SM; Saffer H; Thomas D; Jilani I; Kantarjian HM; Keating MJ; Albitar M
Blood; 2003 Apr; 101(7):2507-13. PubMed ID: 12446458
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
Jacob MC; Favre M; Lemarc'Hadour F; Sotto MF; Bonnefoix T; Sotto JJ; Bensa JC
Am J Hematol; 1992 Jan; 39(1):45-51. PubMed ID: 1531569
[TBL] [Abstract][Full Text] [Related]
6. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
8. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
Bhat SA; Czuczman MS
Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
[TBL] [Abstract][Full Text] [Related]
9. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract][Full Text] [Related]
10. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
[TBL] [Abstract][Full Text] [Related]
11. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry.
Pevna M; Doubek M; Coupek P; Stehlikova O; Klabusay M
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):411-8. PubMed ID: 25066039
[TBL] [Abstract][Full Text] [Related]
12. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma.
Gonzalez CL; Medeiros LJ; Jaffe ES
Am J Clin Pathol; 1991 Jul; 96(1):81-9. PubMed ID: 2069139
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
14. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
16. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
17. CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity.
Barakzai MA; Pervez S
Indian J Pathol Microbiol; 2009; 52(1):6-9. PubMed ID: 19136769
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
20. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]